The studies examining the effects of renin‐angiotensin‐aldosterone system pathway genetic variation (and targeting of that pathway with angiotensin‐converting enzyme inhibition)113, 114 as well those studies assessing the effect of adrenergic pathway variation on clinical outcomes117 in patients with CHD indicate that therapeutic approaches tailored to specific genetic profiles may help improve outcomes. The gene discussed is REN; the disease is coronary artery disorder.